Product information and disease descriptionProduct descriptionProduct informationPharmacology
Mechanism of action
5 evidence topics · 4 sources
Transient CAR expression from RNA without genomic modification
“Engineering of cells using RNA offers distinct advantages toward this goal by exploiting transient CAR expression.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“This characteristic enables dosing at levels that are immediately therapeutic and that exhibit a built-in proliferative check: CAR RNA degrades during cell division.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“As a result, RNA cell therapy can be administered without lymphodepletion and in the outpatient setting, also eliminating the risk of secondary malignancies because no genomic modification occurs.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
CAR-positive cell load limited by the administered dose
“Since the CAR-encoding mRNA does not replicate together with the activated and proliferating rCAR T-cells, the load of CAR+ cells is determined and limited by the administered dose, and declines over time, potentially enabling more precise PK control over the therapy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Because our approach uses ex vivo T-cell proliferation, it does not require the specific cytokine environment induced by lymphodepletion.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Only CD8+ T-cells are used for manufacturing since CD4+ T-cells are known for their memory function, rather than direct killing function, which is not relevant to RNA-transfected CAR T-cells that express the CAR molecule over days.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Target antigen: BCMA on plasma cells
Proposed mechanism: preferential depletion of BCMA-high plasma cells and a precision immune reset
“Potential mechanisms could involve precision ablation (for example, direct cytotoxicity) or interference (for example, trogocytosis) on the BCMAhi subset comprising pathogenic PCs and other cells such as pDCs.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Functionally, therefore, Descartes-08 may preferentially deplete PCs expressing high levels of BCMA, which, in patients with autoimmune disease, is preferential to PCs producing pathogenic autoantibodies.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Directly testing these hypotheses is a clinical challenge in the context of autoimmunity because the key target cells are predominantly located outside of circulation—PCs resident in the bone marrow and activated pDCs and B cells in inflamed tissue or lymphatics11,37,41–43.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Mechanism compared with complement inhibitors, FcRn inhibitors, and DNA-based CAR-T cell therapies
“These technologies include FcRn inhibitors and complement inhibitors that directly target circulating antibodies and antibody effector function, respectively; both technologies involve ongoing treatment to maintain effect48–50.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Further, emerging T cell therapies often involve lymphodepletion, viral vectors and targeting of CD19 that result in non-specific depletion of B cells and, consequently, immunoglobulins and vaccine titers2,45,46.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote